Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings
MIRM·Reported May 8, 2024·After market close
Mirum Pharmaceuticals, Inc. reported Q1 2024 revenue of $69.2M, missed analyst consensus of $70.2M by $948.0K. Diluted EPS came in at $-0.54, missed the $-0.40 consensus by $0.14.
Revenue
$69.2Mmissed by $948.0K
Consensus: $70.2MDiluted EPS
$-0.54missed by $0.14
Consensus: $-0.40
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Mirum Pharmaceuticals, Inc.'s Q1 2024 earnings report.
Mirum Pharmaceuticals, Inc. (MIRM) reported Q1 2024 earnings on May 8, 2024 after market close.
Mirum Pharmaceuticals, Inc. reported revenue of $69.2M and diluted EPS of $-0.54 for Q1 2024.
Revenue missed the consensus estimate of $70.2M by $948.0K. EPS missed the consensus estimate of $-0.40 by $0.14.
You can read the 10-Q periodic report (0001759425-24-000019) directly on SEC EDGAR. The filing index links above go to sec.gov.